ESRRG: Estrogen-related receptor gamma
Orphan receptor that acts as a transcription activator in the absence of bound ligand.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ESRRG, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Afimoxifene | Phase 3 | Ascend Therapeutics US | Small molecule | AntagonistEstrogen-related receptor gamma antagonist | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | Afimoxifene | Phase 2 | Active, not recruiting | Northwestern University | Jul 5, 2019 |
- Movement disorder0.47
- Risk-taking behaviour0.43
- Abnormality of the skeletal system0.41
- Intelligence0.40
- Alcohol drinking0.39
- Atrial fibrillation0.38
- Attention deficit-hyperactivity disorder0.37
- Substance abuse0.37
- Refractive error0.37
- Breast carcinoma0.36
- Eye disorder0.35
- Stroke disorder0.33
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4245, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P62508, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets